East Windsor, NJ—A new study published in Journal of Experimental and Clinical Cancer Research found that Sabinsa’s Curcumin C3 Complex in combination with BioPerine (CBP) has an inhibitory effect on malignant mesothelioma (MM) cells.
MM is an aggressive form of cancer primarily associated with exposure to asbestos fibers. It has a long latency, non-specific clinical symptoms, and is resistant to chemotherapy. A press release on the topic says that this latest study explored the use of CBP in both drug susceptible and drug-resistant MM cancer cell-types. Researchers found that CBP impaired the viability of cancer cells, self-renewal ability of cancer cells, cell proliferation rate, and cell migration as assessed by wound-healing assay. Onset of apoptosis of cancer cells was determined to occur by activation of intrinsic pathways through an altered ratio of Bax/BC12 proteins.
The authors noted that it might be possible to include CBP administration with drug regimens for MM.
Related: Study: Curcumin C3 Complex May Benefit Chemotherapy Patients
Study: Curcumin, Resveratrol Possible Anti-Cancer Compounds
Curcumin and BioPerine Shown to Improve Gut Microbiota
Dr. Muhammed Majeed, founder of Sabinsa, said in the release: “Research suggesting that utilization of our flagship ingredients in combination with standard pharmacological therapies may pave the way to developing alternative and more effective treatment for MM is encouraging, as its prognosis, at present, remains poor. We continue to be gratified that researchers throughout the world and investigating our Curcumin C3 Complex and BioPerine for advances such as this.”